Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Treatment of Tuberculosis ? Adjuvant Therapies to Increase the Efficiency of Antibiotic Treatments

Posted Nov 17 2011 7:00pm

Description of Invention:
There is growing evidence that resistance to Mycobacterium tuberculosis infection is governed in large part by the regulation of host cell death. Lipid mediators called eicosanoids are thought to play a central role in this process. The subject invention is a novel method of enhancing the efficacy of antibiotic treatments for Mycobacterium tuberculosis infection by co-administering an inhibitor of 5-lipoxygenase and a COX-2 dependent prostaglandin. Inhibition of 5-lipoxygenase and treatment with prostaglandin E2 results in alteration of the eicosanoid balance. The synergistic effects of altering the eicosanoid balance and treatment with antibiotics is believed to result in more efficient reduction of the bacterial burden and thus, the period of antibiotic administration and antibiotic dosage could potentially be reduced. In vivo data from mouse models can be provided upon request.

Applications:
The subject invention can be used as an adjuvant therapy for existing antibiotic treatment regiments against tuberculosis.

Advantages:
The disclosed method can be applied to increase the efficacy of existing antibiotic treatments for tuberculosis, potentially reducing both the duration and dosage of the antibiotic treatment.

Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:
Katrin D Mayer (NIAID)
Bruno Bezerril D Andrade (NIAID)
F. Alan Sher (NIAID)
Daniel L Barber (NIAID)


Patent Status:
HHS, Reference No. E-189-2011/0
US, Application No. 61/515,229 filed 04 Aug 2011
US, Application No. 61/515,237 filed 04 Aug 2011


Collaborative Research Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize adjuvant therapy for antibiotic treatment regiments against tuberculosis. For collaboration opportunities, please contact Katrin Mayer. Ph.D. at mayerk@niaid.nih.gov or 301-594-8061.


For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 2337

Updated: 11/2011

Post a comment
Write a comment:

Related Searches